Generic Name and Formulations:
Clindamycin (as phosphate) 2%; vag crm.
Indications for CLINDESSE:
1 applicatorful intravaginally once.
History of enteritis or colitis.
Monitor for pseudomembranous colitis. Do not rely on contraceptive diaphragm or condom concurrently or for 5 days after treatment. Do not have vaginal intercourse or use tampons or douches during treatment. Pregnancy (Cat.B). Nursing mothers: not recommended.
May potentiate neuromuscular blockers.
Fungal vaginosis, vulvovaginal pruritus, headache.
Prefilled applicator (5g )—1
Clinical Pain Advisor Articles
- Deaths After Nonfatal Opioid Overdose: Causes and Risk Factors
- Treatment for Opioid Use Disorder Associated With Reduced Risk for Opioid-Related Deaths
- Opioid-Free Analgesia Use for Postsurgical Pain Limited
- Clonidine May Not Improve Post-Cesarean Delivery Analgesia
- No Added Value With Liposomal Bupivacaine Following TKA With Peripheral Nerve Block
- Recommendations for Perioperative Pain Management in Patients With Opioid Tolerance
- Vertebroplasty Comparable With Placebo for Acute Vertebral Compression Fractures
- Capsaicin 8% Patch May Be Effective in Neuropathic Pain
- Detox vs Medication-Assisted Treatment for Opioid Use Disorder in Pregnancy: Expert Roundtable
- Prior Authorization Policy May Help Reduce Long-Acting Opioid Use
- Opioid-Related Deaths Represent Significant Public Health Burden
- Addressing Confidentiality Concerns With Electronic Access to Pediatric Medical Records
- Opioid-Related Adverse Events Common After Invasive Procedures
- Diagnosis and Treatment of Migraine in Children Should Consider Atopy
- Led by AG Sessions, DOJ Declines to Defend ACA Against Federal Lawsuit